Melissa Lyle, MD: Hello, everyone. I am Melissa Lyle, cardiology fellow at Mayo Clinic. Today, we will be discussing the management of Fontan patients. I am joined by my colleagues, Dr Alexander Egbe ...
PHILADELPHIA — In a phase 3 study, the phosphodiesterase-5 (PDE-5) inhibitor udenafil (Mezzion Pharma) did not improve the primary end point of oxygen consumption at peak exercise, but was associated ...
Dr Julian Alexander Härtel and Dr Nicole Müller from the Department of Paediatric Cardiology at the UKB, who jointly led the study, with study nurse and coordinator Ute Baur. The researchers conducted ...
SEOUL, South Korea, Aug. 12, 2025 /PRNewswire/ -- A newly published post-hoc analysis of the landmark FUEL (Fontan Udenafil Exercise Longitudinal) Trial demonstrates that udenafil, a PDE5 inhibitor, ...
Mezzion Pharmaceuticals Inc, a clinical-stage rare disease biopharmaceutical company developing the first treatment specifically for people born with single ventricle congenital heart disease (SV-CHD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback